CSL company profile
Company profile
CSL has 29,000 employees and is headquartered in Melbourne, Australia.
Known to many through its CSL Behring plasma products, CSL Seqirus influenza vaccines and CSL Vifor iron deficiency and nephrology treatments, the company researches, develops, manufactures and distributes biopharmaceutical products and vaccines. Its therapeutic areas include immunoglobulins, immunology, haematology, cardiovascular and renal conditions, and vaccines, with gene therapies and recombinant products also part of its portfolio. Sales reach customers in Australia, the United States, Germany, the United Kingdom, Switzerland, China and Hong Kong, as well as internationally. The Seqirus unit also supplies pandemic services to governments.
In the fiscal year ended June 2026, revenue reached 15.8 billion US dollars, up 1.5% from the previous year, while the company posted a net loss of 2.6 billion US dollars. CSL had 29,000 employees and is headquartered in Melbourne, Australia, where it was founded in 1916. It was formerly known as Commonwealth Serum Laboratories Limited and adopted the CSL Limited name in October 1991.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Headquarters
- 655 Elizabeth Street, 3000, Melbourne
- Employees
- 29,000
- Chief executive
- Gordon Naylor
- Founded
- 1916
- Fiscal year
- July - June
- Listing
- CSL · ASX
- Indices
- S&P/ASX 200
- Currency
- AUD
- ISIN
- AU000000CSL8
- Website
- csl.com
CSL and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| CSLCSL | Australia | $64.31B | 29,000 | 26.8% | — |
| Samsung Biologics207940 | South Korea | $49.26B | 5,326 | 45.5% | 31.2 |
| Celltrion068270 | South Korea | $36.53B | 2,956 | 31.6% | 31.4 |
| WuXi Biologics (Cayman)2269 | Hong Kong SAR China | $24.29B | 14,705 | 32.4% | 35.1 |
| Innovent Biologics1801 | Hong Kong SAR China | $18.84B | 8,754 | 7.4% | 111.5 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $13.65B | 2,300 | -0.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
